| DB ID | MyCo_6596 |
| Title | Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions |
| Year | 2016 |
| PMID | 27181045 |
| Fungal Diseases involved | Invasive candidiasis |
| Associated Medical Condition | ICU patients with severe abdominal conditions |
| Genus | Candida |
| Species | albicans |
| Organism | Candida albicans |
| Ethical Statement | The study protocol was approved by the Ethics Committee of Hospital Universitario de Valme (Sevilla, Spain) and the Spanish Agency for Medicines and Health Care Products (AEMPS). The codes and dates of approval of the study protocol were CEIC-A1, ref. 350/12 (May 29, 2012) for the Ethics Committee of Hospital de Valme, and September 14, 2012 for AEMPS. Informed consent was obtained from the patients or their legal representatives. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | CAGTA + BDG |
| Biomarker Full Name | Candida albicans germ tube antibody + 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Spain |
| Cohort | Between November 1, 2012 and February 28, 2014, all consecutive adult non-neutropenic patients with SAC on ICU admission and an expected stay of ≥ 7 days were included in a prospective, cohort, observational, and multicenter study. A prospective study of 233 non-neutropenic patients with SAC on ICU admission and expected stay ≥ 7 days. CAGTA (cutoff positivity ≥ 1/160), BDG (≥80, 100 and 200 pg/mL), mannan-Ag (≥60 pg/mL), mannan-Ab (≥10 UA/mL) were measured twice a week, and Candida DNA only in patients treated with systemic antifungals. |
| Cohort No. | 233 |
| Age Group | 66.7 ± 13.2 |
| P Value | p< 0.05 |
| Sensitivity | 90.30% |
| Specificity | 42.10% |
| Positive Predictive Value | 0.193 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Accurate and timely diagnosis of invasive candidiasis (IC) from the patient’s perspective and to optimize antifungal therapy in the intensive care unit (ICU) setting remains a topic of great interest. The use of single or combined biomarkers, such as (1→ 3)-ß-D-glucan (BDG), Candida albicans germ tube antibody (CAGTA), mannan antigen (mannan-Ag), anti-mannan antibodies (mannan-Ab), and polymerase chain reaction (PCR) detection of Candida DNA has received increasing at- tention, but the appropriate incorporation into clinical practice remains controversial. We investigated the performance of these five tests, alone and in combin- ation, for discriminating IC in critically ill patients with severe abdominal conditions (SAC). |
| Technique | Immunological assay |
| Analysis Method | Serology Based |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | FDA approved Fungitell assay, Serology Based Immunofluorescence test |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
